Link Pharma Chem Limited has confirmed the re-appointment of Mr. Satish G. Thakur as Chairman and Whole-time Director for a three-year term effective June 24, 2026. The resolution was passed during the company’s 41st Annual General Meeting (AGM) held on August 20, 2026.

The company also re-appointed Mr. Rishikesh Thakur as Managing Director for a three-year term effective September 24, 2026. Shareholders approved all six ordinary and special resolutions with overwhelming support, securing 99.74% affirmative votes across the board. The virtual meeting was scrutinized by M/s. Vijay Bhatt & Co., Company Secretaries, Vadodara.

Voting Participation

As per the record date of August 13, 2026, the company had a total of 6,004 shareholders. Of these, 47 members attended the meeting through video conferencing, comprising three promoters and 44 public shareholders.

The total number of votes polled was 2,618,698, representing 58.97% of the outstanding shares held by eligible voters. The promoter group held 2,326,936 shares and voted in favor of all resolutions. Public non-institutional shareholders polled 291,762 votes, with 284,823 cast in favor and 6,939 against.

Resolutions Passed

All resolutions were passed with the requisite majority. No invalid votes were recorded during the process.

Management Profile & Attendance

Mr. Satish G. Thakur, who holds a B.Sc. and L.Tech degree, has been associated with the company since its incorporation. He brings more than 43 years of experience in the industry, with expertise in project design and development. He is the father of Mr. Rishikesh Thakur, Managing Director.

Key management personnel present included Mr. Rishikesh Thakur, Managing Director; Mrs. Rachna Ghai, Independent Director; Mr. Rohit J Shah, Independent Director; and Mrs. Rangoli S Gada, Independent Director. Mr. Sanjib Dutta, Chief Financial Officer, and Mrs. Komal Bhojwani, Company Secretary, were also in attendance.

Mr. Satish G. Thakur chaired the proceedings. Five shareholders participated in the question-and-answer session, with queries addressed by the Managing Director.

Mr. Rishikesh Thakur holds a degree in B. Eng. in Polymer from London Metropolitan University. He has more than 15 years of experience in the chemical business, including manufacturing, research and development, and project development.

The Company Secretary confirmed that the scrutinizer’s report and e-voting results have been submitted to the BSE within the stipulated timeframe.

Link Pharma Chem Limited returned to profitability in Q1FY26, reporting a net profit of ₹31.83 crore for the quarter ended June 30, 2026, reversing a net loss of ₹40.86 crore in the preceding quarter. The company’s revenue from operations rose 12.2% year-on-year to ₹876.84 crore, driven by higher operational income and significant gains from other sources. This turnaround marks a strong start to FY26, with pre-tax profits reaching ₹38.87 crore against a loss of ₹49.00 crore in Q4FY25.

The Board of Directors approved the unaudited financial results at a meeting held on August 5, 2026. Pursuant to Regulation 47(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Link Pharma Chem published extracts of its financial results in Business Standard (English edition) and Loksatta (Gujarati edition) on August 6, 2026. The results were reviewed by statutory auditors CNK & Associates LLP under Standard on Review Engagements (SRE) 2410.

Financial Performance Highlights

Total income for the quarter reached ₹911.73 crore, supported by both operational revenue and other income. Other income surged to ₹34.89 crore from ₹20.92 crore in Q1FY25, largely due to fair value gains on financial assets. Total expenses increased to ₹872.86 crore from ₹751.43 crore in the corresponding period last year, primarily due to higher material costs and inventory changes.

What the Numbers Show

A key driver of the current quarter’s profitability was the composition of other income. Under Ind AS 109, the company values its investments at market prices, with fair value gains accounted for in other income. In Q1FY26, fair value net gains on financial assets designated at FVTPL amounted to ₹18.47 crore, compared to a loss of ₹2.86 crore in the previous quarter. Excluding these fair value adjustments, "adjusted other income" stood at ₹16.42 crore, a sharp increase from ₹1.96 crore in Q1FY25. This indicates that while operational revenues grew steadily, a substantial portion of the quarter’s income boost came from investment revaluations rather than core operating margins alone.

Earnings per share (EPS) improved to ₹0.72 from a negative ₹0.92 in the prior quarter. For the full fiscal year FY25, the company had reported a net profit of ₹7.69 crore on revenues of ₹2,743.15 crore. The current quarter’s results suggest a stronger start to FY26, though investors should note the volatility in other income components linked to market valuations.